TY - JOUR
T1 - Diagnosis and management of AML in adults :
T2 - 2022 recommendations from an international expert panel on behalf of the ELN
AU - Döhner, Hartmut
AU - Wei, Andrew H.
AU - Appelbaum, Frederick
AU - Craddock, Charles
AU - DiNardo, Courtney D.
AU - Dombret, Hervé
AU - Ebert, Benjamin L.
AU - Fenaux, Pierre
AU - Godley, Lucy A.
AU - Hasserjian, Robert P
AU - Larson, Richard A
AU - Levine, Ross L.
AU - Miyazaki, Yasushi
AU - Niederwieser, Dietger
AU - Ossenkoppele, Gert
AU - Röllig, Christoph
AU - Sierra, Jorge
AU - Stein, Eytan M.
AU - Tallman, Martin S.
AU - Tien, Hwei-Fang F.
AU - Wang, Jianxiang
AU - Wierzbowska, Agnieszka
AU - Löwenberg, Bob
PY - 2022
Y1 - 2022
N2 - The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.
AB - The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.
KW - Adult
KW - Antineoplastic Agents
KW - Humans
KW - Leukemia, Myeloid, Acute
KW - Mutation
KW - Neoplasm, Residual
KW - Nucleophosmin
KW - Prognosis
KW - Proto-Oncogene Proteins c-bcl-2
U2 - 10.1182/blood.2022016867
DO - 10.1182/blood.2022016867
M3 - Article
C2 - 35797463
SN - 0006-4971
VL - 140
SP - 1345
EP - 1377
JO - Blood
JF - Blood
IS - 12
ER -